Nestlé to buy rest of stake in Aimmune Therapeutics

Aimmune's Palforzia peanut allergy treatment, which recently gained US approval for children, has sales potential of $1bn

Zurich —

Nestlé said in a statement that its offer for Aimmune values the California-based biopharmaceutical firm, which it has been working with since 2016 and in which it already has a stake of 25.6%, at $2.6bn. , Behar said. The deal is expected to add to organic growth in 2021 and to cash earnings by 2022/2023.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

BDliveSA /  🏆 12. in ZA

South Africa Latest News, South Africa Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Berkshire buys stakes in Japanese trading companiesWarren Buffett’s firm acquired about 5% in Itochu, Marubeni, Mitsubishi, Mitsui & Co and Sumitomo over the past twelve months
Read more »

Famous Brands sells controlling stake in TashasGroup offloads 51% stake in restaurant group to Sideris family, who holds remaining 49%
Read more »

Rest in power, King T'Challa: Fellow Marvel stars and more pay tribute to Chadwick Boseman | ChannelRest in power, King T'Challa: Fellow Marvel stars and more pay tribute to Chadwick Boseman
Read more »

Make time to rest or the world will steal it from youSwitching off confers competitive advantages at work, but most are really bad at it
Read more »

Make time to rest or the world will steal it from youSwitching off confers competitive advantages at work, but most are really bad at it
Read more »

WATCH: Drama unfolds at Lebogang Khitsane's memorial serviceLebogang Khitsane, who once said he wanted to be remembered as “the Steve Jobs of tombstones”, will be laid to rest on Tuesday.
Read more »